U.S. Markets close in 5 hrs 22 mins

Cara Therapeutics: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of Cara Therapeutics (NASDAQ:CARA) rose 0.62% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 52.70% year over year to ($0.35), which beat the estimate of ($0.60).

Revenue of $9,266,000 higher by 60.17% year over year, which beat the estimate of $4,770,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 09, 2020

View more earnings on CARA

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/42euzka8

Recent Stock Performance

Company's 52-week high was at $26.67

Company's 52-week low was at $8.88

Price action over last quarter: down 16.75%

Company Profile

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.